1. Home
  2. GDHG vs TVRD Comparison

GDHG vs TVRD Comparison

Compare GDHG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Golden Heaven Group Holdings Ltd.

GDHG

Golden Heaven Group Holdings Ltd.

N/A

Current Price

$1.77

Market Cap

35.1M

ML Signal

N/A

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.84

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDHG
TVRD
Founded
2008
2017
Country
China
United States
Employees
N/A
12
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.1M
34.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
GDHG
TVRD
Price
$1.77
$2.84
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
4.4K
45.6K
Earning Date
07-11-2025
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$2.75
52 Week High
$8.69
$43.65

Technical Indicators

Market Signals
Indicator
GDHG
TVRD
Relative Strength Index (RSI) 40.04 34.12
Support Level $1.53 N/A
Resistance Level $1.98 $4.32
Average True Range (ATR) 0.17 0.29
MACD -0.01 -0.10
Stochastic Oscillator 9.52 2.34

Price Performance

Historical Comparison
GDHG
TVRD

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: